HelioLiver™ LDT · A Simple Blood Test for Liver Cancer

Saving Lives by Detecting Cancer Early

At Helio, we're on a mission to save lives. With just a simple blood test, we empower more people to check for cancer early and often, when it is most treatable, so everyone has the best chance to beat it.

Discover HelioLiver Explore Our Platform

Validated in the CLiMB trial Published in the Journal of Hepatology

Helio Genomics scientist analyzing a blood-based sample in the lab

90% survival when cancer is
caught at an early stage

4× more Stage I cancers
detected vs. ultrasound

HelioLiver™ · A simple blood test for liver cancer

HelioLiver™ LDT

A simple blood test for the early detection of liver cancer (HCC), now available through Quest Diagnostics.

Order HelioLiver Learn More

Our Mission

Finding Cancer Early Is the Key to Defeating It

For the majority of cancers, 90% of people survive if their cancer is detected at an early stage. But many of today's diagnostics are inconvenient, expensive, and poor predictors of early-stage cancer.

Now with Helio, finding cancer early is as simple as a blood draw. We focus our work on early detection, when treatment is most effective, and the chances of beating cancer are highest.

5-Year Survival by Stage at Detection Majority of cancers

Detected early stage 90%

Detected late stage 21%

4× higher Catching cancer early can quadruple the chance of survival. Source: SEER Database.

HelioLiver LDT Collection Kit box held in two hands

Available now · Quest Diagnostics

Our First Commercial Test

Detect Liver Cancer Earlier Than Ever Before

HelioLiver™ LDT is the first test built on the Helio platform, and it's available for clinical use today. In the CLiMB trial, this groundbreaking blood test detected Stage I liver cancer four times more often than ultrasound, the current standard of care. By reading cell-free DNA methylation alongside protein tumour markers and your clinical history, HelioLiver finds hepatocellular carcinoma (HCC) earlier, when it's smaller, more treatable, and curative options like surgery and transplant are still on the table.

40% vs 10%

Stage I HCC detection, HelioLiver vs ultrasound

29% vs 0%

sensitivity for lesions under 2 cm

10–14 days

average turnaround time

Validated in the CLiMB trial and published in the Journal of Hepatology, May 2026. Now available to order through Quest Diagnostics.

Discover HelioLiver LDT For Healthcare Providers

The Helio Platform

One Platform. A Smarter Way to Detect Cancer.

HelioLiver is the first test built on Helio's broader AI-powered platform, which reads cell-free DNA methylation patterns to detect cancer early, and is designed to do more than detect a single disease.

Early Detection

We read proprietary methylation patterns in cell-free DNA that can reveal cancer as early as Stage I from a simple blood draw, when treatment works best.

Disease Monitoring

Beyond detection, our platform is designed to monitor minimal residual disease, helping clinicians track response and guide decisions over time.

Powered by AI

Machine learning turns complex biomarker data into clear, reliable answers, built on proprietary, patented science developed over nearly a decade.

Explore the Technology

The Science & Proof

Backed by Nearly a Decade of Peer-Reviewed Science

Since 2016, Helio Genomics has pioneered the use of DNA methylation for early cancer detection, with foundational research published in some of the world's most respected scientific journals.

2016

Founded with a proprietary, patented methylation profile of novel cancer biomarkers

2017

Early methylation detection research was published in Nature Materials and PNAS

2021

An AI and machine learning detection method was published in Nature Communications

2026

CLiMB trial results published in the Journal of Hepatology

Read Our Research

Why It Matters

Timing Matters. Early Detection Can Lead to Better Outcomes.

Fewer than half of all liver cancers in the US are diagnosed at an early stage, while the disease is still localised. Early detection significantly improves outcomes, allowing for a higher survival rate and opening the door to potentially curative treatment options, such as surgery and transplant.

Learn About Early Detection

37%

Early-stage
(localised)

Advanced-stage
(distant)

Five-year relative survival falls from localised (early-stage) to distant (advanced-stage) liver cancer · SEER Database

Partners & Recognition

We Collaborate with Leaders in Clinical Care

Bringing this groundbreaking work to patients takes partnership. Helio Genomics collaborates with leaders in clinical care and technology, including Quest Diagnostics, a strategic partnership with Syneos Health, and the Microsoft-co-chaired Rural Health Transformation Collaborative.